- Home
- WHF vs NRXP Comparison
WHF vs NRXP Comparison
Compare WHF & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | NRXP |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 151.1M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WHF | NRXP |
|---|---|---|
| Price | $7.94 | $2.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $7.83 | ★ $38.50 |
| AVG Volume (30 Days) | 87.3K | ★ 635.9K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | ★ 13.57% | N/A |
| EPS Growth | 31.91 | ★ 69.70 |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | $3.38 | $1,507.30 |
| P/E Ratio | $17.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $1.65 |
| 52 Week High | $7.84 | $5.06 |
Technical Indicators
Market Signals| Indicator | WHF | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 69.29 | 26.31 |
| Support Level | $6.89 | $1.68 |
| Resistance Level | N/A | $2.49 |
| Average True Range (ATR) | 0.23 | 0.16 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 86.99 | 4.07 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.